C07D401/10

CYCLOPROPYLAMINES AS LSD1 INHIBITORS
20180000805 · 2018-01-04 ·

This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.

CYCLOPROPYLAMINES AS LSD1 INHIBITORS
20180000805 · 2018-01-04 ·

This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.

NITROGEN-CONTAINING HETEROCYCLIC COMPOUND

The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.

The present invention relates to a compound represented by the formula (I) or a salt thereof.

##STR00001##

wherein each symbol is as described in the specification, or a salt thereof.

CYCLIC UREAS AS INHIBITORS OF ROCK

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

##STR00001##

CYCLIC UREAS AS INHIBITORS OF ROCK

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

##STR00001##

Tetrazolones as a Carboxylic Acid Bioisosteres
20180002297 · 2018-01-04 ·

The present disclosure provides compounds that include a tetrazolone derivative of a carboxyl group of an active agent. This disclosure also relates to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

Tetrazolones as a Carboxylic Acid Bioisosteres
20180002297 · 2018-01-04 ·

The present disclosure provides compounds that include a tetrazolone derivative of a carboxyl group of an active agent. This disclosure also relates to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

ORGANIC ELECTROLUMINESCENT DEVICE

In the organic electroluminescent device having at least an anode, a hole injection layer, a first hole injection layer, a second hole injection layer, a light emitting layer, an electron transport layer and a cathode in this order, the hole injection layer includes an arylamine compound of the following general formula (1) and an electron acceptor.

##STR00001##

In the formula, Ar.sub.1 to Ar.sub.4 may be the same or different, and represent a substituted or unsubstituted aromatic hydrocarbon group, a substituted or unsubstituted aromatic heterocyclic group, or a substituted or unsubstituted condensed polycyclic aromatic group.

ORGANIC ELECTROLUMINESCENT DEVICE

In the organic electroluminescent device having at least an anode, a hole injection layer, a first hole injection layer, a second hole injection layer, a light emitting layer, an electron transport layer and a cathode in this order, the hole injection layer includes an arylamine compound of the following general formula (1) and an electron acceptor.

##STR00001##

In the formula, Ar.sub.1 to Ar.sub.4 may be the same or different, and represent a substituted or unsubstituted aromatic hydrocarbon group, a substituted or unsubstituted aromatic heterocyclic group, or a substituted or unsubstituted condensed polycyclic aromatic group.

PYRIMIDINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICES

According to the present invention, there are provided pyrimidine derivatives represented by the following general formula (1). The pyrimidine derivatives of the invention are novel compounds and feature (1) good electron injection property, (2) high electron mobility, (3) excellent hole blocking property, (4) good stability in their form of thin films, and (5) excellent heat resistance.

##STR00001##